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1. Introduction  
1.1 Historical notes 
The last decade has witnessed profound changes in the treatment of chronic myeloid 
leukemia (CML). Previously, therapeutic options were restricted to the use of conventional 
chemotherapeutic agents such as hydroxyurea (Goldman, & Marin, 2003) and busulfan 
(Brodsky, 1993). These were essentially cosmetic treatments, offering only palliative care, and 
not substantially altering the natural history of the disease. Later in the 90s interferon alpha 
(IFNǂ), was introduced in the therapeutic armamentarium for CML patients (Goldman, 
2003). When used at high doses, this agent proved to be superior to conventional 
chemotherapy in terms of hematological and cytogenetic response rates. In particular, 9- or 
10-year overall survival (OS) rates in the range of 27% to 53% (Bonifazi, 2001) have been 
reported. However, residual leukemia was still detectable at the molecular level in the vast 
majority of patients (Baccarani, 2003). Overall, these observations indicated that none of 
these treatment options were curative for CML and allogeneic bone marrow transplantation 
remained the only disease-eradicating therapy, albeit at the price of substantial treatment-
related mortality, especially for the higher EBMT risk score patients (Gratwohl,  1998 ; 
Baccarani, 2006; Passweg , 2004).  
1.2 The modern era of CML treatment: the TKi revolution 
In 1960 Nowell and Hungerford, working in Philadelphia, noticed the consistent presence of 
a small abnormal chromosome in the leukemic cells of CML patients (Nowell & Hungerford, 
1960). Strikingly, this abnormality was present in nearly all cases and in all leukemic cells of 
a single patient, indicating that it could represent a disease marker and, possibly, a 
tumorigenic alteration. The abnormal chromosome was named “Philadelphia”. Since then, 
the development of more sophisticated and reliable diagnostic technologies has led to 
precise characterization of the Philadelphia chromosome (Ph) as the result of the reciprocal 
translocation t(9;22), as well as the corresponding molecular defect, consisting in the 
formation of a chimeric oncogene, BCR-ABL, from the juxtaposition of the broken ends of 
chromosomes 9 (ABL) and 22 (BCR) (Rowley, 1973) (Fig.1). Molecular biology studies 
suggested that the product of BCR-ABL was an oncoprotein, provided with constitutive 
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phosphorylating activity (Gale & Canaani 1984; Sefton, 1981; Witte, 1980). This was shown to 
promote escape from apoptosis, uncontrollable proliferation, diminished adherence to the 
marrow stroma, and significant genetic instability (Lugo, 1990; Melo,V 2004) (Fig.2). Most 
importantly, when expressing BCR-ABL in animal models, the investigators demonstrated 
that BCR-ABL, as the sole oncogenic event, was able to induce leukemia (Lugo, 1990; Melo, 
2004). 
In the late 80s the tyrosine kinase inhibitor (TKi) program started and one leading 
compound of the 2-phenylaminopyrimidine class capable of inhibiting the ABL kinase was 
identified: STI571, or imatinib (Zimmermann, 1996; Druke, 1996; Buchdunge, 1996; Druker & 
Lydon 2000; Carrol, 1997). Since then, the drug has rapidly undergone preclinical and clinical 
development until FDA approval only 3 years after the initiation of the phase I study 
(Druker, 2001a; Druker, 2001b; Kantarjian, 2002; Sawyers, 2002). In June 2000 the landmark 
International Randomized Study of Interferon and STI571 (IRIS) was initiated. More than 
1000 previously untreated CML patients in chronic phase (CP) were randomly allocated to 
either IFN+cytosine arabinoside (ARA-C) or imatinib. The remarkable superiority of the 
latter in terms of complete hematologic, major and complete cytogenetic responses, as well 
as rates of progression to advanced disease phases, namely accelerated phase (AP) or blastic 
phase (BP), led to early closure of the study and most of IFN+ARA-C patients being crossed 
over to imatinib (Druker, 2006; O'Brien, 2003). 
 
 
Fig. 1. Schematic diagram of the translocation that results in Philadephia chromosome. The 
ABL gene resides on the long arm of chromosome 9, the BCR gene resides on the long arm of 
chromosome 22. As a result of the (9;22) translocation, a BCR-ABL gene is formed on the 
derivative chromosome 22 (Philadelphia chromosome) 
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Fig. 2. Schematic signalling pathways activated by BCR-ABL that contribute to growth and 
survival   
Overall, the introduction of TKis in clinical practice has brought dramatic improvement in 
the rates and quality of hematologic and cytogenetic responses and has led to a paradigm 
shift in the treatment approach of CML patients. These drugs have also defined our current 
view of desirable cancer therapy as a targeted tumor cell killing using agents that directly 
interfere with oncogenetic mechanisms. Finally, CML is a significant example of the 
usefulness of molecular. These techniques may also be used to predict early treatment 
failure and to direct therapeutic choices accordingly. This chapter covers various aspects of 
CML patient molecular monitoring, including the use of well-established diagnostic 
techniques, past and ongoing standardization practices, and the role of molecular 
diagnostics in clinical practice.Some as-yet open issues and unanswered questions in the 
field will also be pointed out. 
2. Assessment and monitoring of CML: Molecular tools 
As most patients treated with TKis achieve a complete cytogenetic remission (CCyR), highly 
sensitive molecular diagnostic techniques have been implemented in parallel with the 
clinical development of these drugs. This has allowed to fully appreciate the potency of 
these compounds and, more importantly, to evaluate leukemic cell clearance and quantify 
residual disease at a much deeper level. These techniques encompass fluorescent in-situ 
hybridization (FISH), reverse transcriptase (RT)-polymerase chain reaction (PCR) and real-
time quantitative (RQ)-PCR, and will be briefly discussed. 
2.1 FISH 
This technique can be used to ascertain the presence of the BCR-ABL fusion gene in a given 
cell sample. FISH allows analysis of both dividing (metaphase) and non-dividing 
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(interphase) cells (Faderl, 1999), and can be performed on either peripheral blood or bone 
marrow samples. A minimum of 200 cells should be analyzed in order for the test to be 
informative (Kantarjian, 2008). Its sensitivity is high and the upper limit of false positivity is 
1% to 5% (Dewald, 1998). The hypermetaphase FISH allows analysis of up 500 cells in 
metaphase per sample and produces no false positive results but cannot be performed on 
peripheral blood samples (Seong, 1995). The dual-color FISH (D-FISH) uses double-color 
probes that allow detection of a fusion signal. In CML, modern D-FISH strategies use a 
“green” probe to identify BCR and a “red” one to highlight ABL. A yellow signal indicates 
the presence of a BCR-ABL fusion sequence (Tefferi, 2005). This technique allows to detect 
not only the presence, but also the copy number of the fusion gene on the Ph, as well as the 
number of any additional BCR-ABL-bearing chromosomes, such as the ones resulting from 
variant translocations, cryptic translocations or insertions (Dewald,  1998). D-FISH has very 
low false-positive rates (≤0.8%) (Wolff, 2007). It should be remembered that D-FISH does not 
substitute for conventional cytogenetics because it will not detect additional cytogenetic 
abnormalities, unless specifically requested. 
CML patients show 85 to 99% of BCR-ABL-positive nuclei in bone marrow before treatment, 
which decrease to less than 1% when therapy is successful (Tefferi, 2005). FISH has been 
evaluated as an alternative to routine marrow cytogenetics for monitoring purposes (Testoni, 
2006). However, up to 18% of patients in CCyR by standard cytogenetics has 1% to more 
than 5% FISH-positive cells (Kantarjian, 2008a). The GIMEMA (Gruppo Italiano Malattie 
Ematologiche Adulto) CML working party has reported that as much as 83% of patients 
having a CCyR by conventional testing, also had <1% of BCR-ABL positive nuclei at 
interphase FISH. Conversely, among patients who had <1% positive nuclei by interphase 
FISH, 98% had a CCyR using conventional cytogentic analysis. Moreover, major molecular 
response rates were significantly higher in patients with <1% positivity by interphase FISH 
compared with patients with positivity rates of 1% to 5% (Testoni, 2009). This data show that 
interphase FISH is more sensitive than conventional karyotyping, and can be used as a 
monitoring tool in patients who are in CCyR as per classical cytogenetics (Quintás-Cardama, 
2011).  
2.2 RT-PCR 
The ABL gene encodes a 145kd non-receptor tyrosine kinase. The breakpoint in ABL occurs 
usually at 5’ (toward centromere) of exon 2 of ABL. The ABL exons 2 (a2), are translocated 
and joined to the major breakpoint cluster region (M-bcr) of the BCR gene on chromosome 
22 between exons 12 and 16 (b1 to b5). The breakpoint locations within BCR fall either 5’ 
between exons b2 and b3 or 3’ between b3 and b4. A BCR-ABL fusion gene with a b2a2 
(40%) or b3a2 (55%) junction is created and transcribed into a 8.5 kb mRNA that encodes for 
a 210 kd fusion protein termed BCR-ABL (Faderl, 1999; Sawyers 1999,Quintás-Cardama & 
Cortes 2006). A second breakpoint involves a minor cluster region on chromosome 22, which 
is located upstream at the e1a2 junction, and gives rise to an mRNA translated into 190kDa 
protein (Okamoto, 1997)(Fig.3). In 5% of cases, alternative splicing produces an e1a2 fusion 
transcript. This encodes a p230 oncoprotein, which appears to be provided with less 
pronounced oncogenic potential.  
PCR is used to detect and measure the amount of specific DNA sequences. For practical 
reasons it is easier to amplify a BCR-ABL mRNA that includes b2a2, b3a2 or e1a2 fusion 
sequences (Hughes, 1990a; Hughes, 1990b). In reverse transcriptase (RT)-PCR disease-specific 
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mRNA is first converted to complementary DNA and subsequently subjected to standard 
PCR (Sawyers,1990;Kawasaki, 1988). The resulting amplified product is then assessed by gel 
electrophoresis. Assay specificity and sensitivity in RT-PCR can be enhanced by the use of 
nested primers (nested RT-PCR) (Biernaux, 1995). Nested RT-PCR, is a two-step process. A 
first pair of PCR primers amplifies the target sequence in a standard RT-PCR. A second pair 
of primers (nested primers) then bind within the primary amplified PCR product to produce 
a second PCR product that is shorter in length. This technique is capable of detecting 1 
leukemic cell in 106 to 107 (Roth, 1992,  Lion, 1999; Lee M 1992,Dhingra K 1992) normal cells. 
Since CML patients in hematologic and cytogenetic remission may still show residual 
leukemic cells at RT-PCR, this technique has extensively been used to assess and monitor 
minimal residual disease in these cases (Cross, 1993a). However, because of the lack of 
quantitative information, positive detection of BCR-ABL transcript provides uncertain 
information and does not allow tracing disease level trends over time. Indeed, some PCR-
positive patients could maintain their minimal disease state and eventually become PCR-
negative while on therapy (Hochhaus, 2000,Hughes, 1991). 
 
 
Fig. 3. Breakpoints within the BCR and ABL genes and corriponding proteins 
2.3 RQ-PCR 
Quantification of specific sequences of DNA has been made possible by the use of RQ-PCR 
(or Q-PCR) (Mensink, 1998). Compared to RT-PCR , RQ-PCR enables accurate quantification 
of gene expression during the exponential phase of the PCR amplification process. This is 
achieved by concomitantly measuring one ubiquitously expressed housekeeping gene, such 
as ABL1, BCR, β2-microglobulin, β-glucuronidase or glucose-6-phosphate dehydrogenase. (Hughes, 
2006)  (Guo, 2002) (Beillard, 2003). Real-time PCR is based on the measurement of 
fluorescence emission during the PCR reaction. The detected fluorescence is proportional to 
the amount of target in the sample. Currently, three different RQ-PCR techniques are 
available: RQ-PCR using SYBR Green I Die, RQ-PCR using hydrolysis probes, RQ-PCR 
using hybridization probes (Gabert, 2003). The Europe Against Cancer (EAC) program 
standardized the RQ-PCR for the detection of residual disease in leukemia. This protocol 
uses the ABI 7700 platform with TaqMan probes that permit analysis of a large number of 
samples in a single run (96-well plate format). The TaqMan technology uses a single internal 
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oligonucleotide probe bearing a 5’ reporter fluorophore and 3’ quencher fluorophore. As 
long as the two fluorochromes are in each other’s close vicinity (probe is intact), the 
fluorescence emitted by the reporter fluorochrome will be “adsorbed” by the quencher 
fluorochrome. During the amplification of the target sequence, the probe is hydrolyzed by 
the nuclease activity of the Taq polymerase, resulting in separation of the reporter and 
quencher fluorochromes and consequently in an increase in fluorescence. During each 
consecutive PCR cycle, this fluorescence will further increase because of the progressive and 
exponential accumulation of free reporter fluorochromes. In the TaqMan technology, the 
number of PCR cycles necessary to detect a signal above the threshold is called the cycle 
threshold (Ct) and is directly proportional to the amount of target present at the beginning 
of the reaction. Using standards or calibrators with a known number of molecules, one can 
establish a standard curve and determine the precise amount of target present in the test 
sample (Gabert ,2003; Mocellin,  2003; Beillard, 2003; van der Velden, 2003 ; White, 2010 ;Cross, 
1993b). A sensitivity of 1 leukemic cell in up to 105 normal elements is achievable with RQ-
PCR. False negatives (lack or sub-optimal integrity of mRNA and/or cDNA) must be 
considered and controlled (Béné & Kaeda, 2009). Although less sensitive than nested RT-PCR, 
RQ-PCR has gained an important role in CML molecular monitoring, especially to identify 
earlier patients not optimally responding to or at high risk of relapse on TKi therapy (Lange, 
2004; Serrano, 2000; Martinelli, 2000). 
3. The international scale 
Molecular diagnostics have been tested as a means of assessing patient prognosis beyond 
the predictive power of cytogenetic tools. However, there has been considerable variability 
in the results of such analyses depending on the particular testing laboratory. 
Harmonization of critical pre-analytical and procedural steps in the PCR technique has 
proven feasible and was the first significant step towards full reproducibility and 
comparability of the quantitative results provided by different laboratories using different 
RQ-PCR platforms around the world (Müller, 2009). 
One turning point in the process of harmonization has been represented by a consensus 
meeting held in Bethesda, MD, USA in 2005. An internationally recognized panel of experts 
aimed at providing recommendations to standardize the measurement of BCR-ABL RNA 
levels in any given laboratory worldwide by means of a reference scale, now known as the 
International Scale (IS) (White, 2010). The IS relies upon two specific concepts: the 
standardized baseline, or IS 100%, which is, by definition, the median pre-treatment level of 
BCR-ABL RNA in early chronic phase CML (as defined in IRIS imatinib trial), and major 
molecular response (MMR), or IS 0.1%, or a 3-log (1,000-fold) drop from the baseline value 
(Hughes, 2003; Branford, 2006). A level of IS 1-2% roughly corresponds to the threshold for 
karyotypic CCyR. Following this line, a “complete molecular remission” was defined as 
undetectable BCR-ABL transcripts, that is, below the sensitivity of the assay. A comparison 
between cytogenetic and molecular response milestones is depicted in Fig 4. The panel 
recommended a desirable test sensitivity of at least IS 0.01% (= 4-log reduction from 
baseline) (Quintás-Cardama, 2011). It is to be noted that original material from the IRIS study 
was limited and therefore is no longer available as primary reference. However, traceability 
to the IRIS scale is provided by the extensive quality control data generated by the Adelaide 
laboratory over a period of several years (Branford, 2008). 
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Fig. 4. Relationship between response, the number of leukemic cells and the level of BCR-
ABL transcript. Reproduced and adapted with permission; Baccarani et al., Blood 2006: Sep 
15;108(6):1809-20. 
3.1 Generation of the IS 
The standardized baseline value was determined by an exchange of reference standards 
with values established in reference labs. Reference and quality control samples would have 
to be widely available for any peripheral laboratory to standardize its internal protocol. The 
easiest way to achieve such standardization is by a laboratory-specific conversion factor 
(CF), established using the Adelaide laboratory process as the initial reference (Branford, 
2008). In order for a certain laboratory to establish its own CF, typically 20-30 samples are 
exchanged with the reference laboratory that span at least 3 logs of detectable transcript 
levels, not exceeding IS 10%, to avoid distortions resulting from different control genes at 
higher disease levels. These samples are then analyzed by both laboratories over a certain 
period of time (to avoid intralab biases) and then compared. The results are plotted on a log 
scale for comparison. Lastly, they are validated through a second material exchange 
(Branford, 2008).  
Currently, there is an ongoing collaborative effort to harmonize 57 different laboratories 
across Europe in the context of the European Treatment and Outcome Study (EUTOS) for 
CML project. The European reference laboratory is in Mannheim, Germany, by direct 
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alignment with results obtained in Adelaide (Müller, 2009). In the first step, samples are 
prepared by the reference lab to specifically reflect 10, 1, 0.1, and 0.01% disease levels. These 
are then shipped to the local laboratory for analysis. The local laboratory in turn sends 
patient samples covering approximately the same transcript levels, using internal protocols, 
as well as duplicate results for the calculation of the CF. This is generated by comparing 
reference and local laboratory values by linear regression. For labs with linear results a 
preliminary CF is calculated, and then validated using the method published by Branford et 
al. (Branford, 2008). Patient samples from the peripheral laboratory are analyzed by the 
reference one. Preliminary CFs are then used to compare the patient sample results from the 
reference laboratory (each multiplied by the Mannheim CF which is 0.878) and local 
laboratories (each multiplied by their respective preliminary CF). Concordance is recorded, 
and calculation adjustments to take bias into account are made (Bland & Altman 1986, 1999, 
Müller, 2009). 
3.2 Beyond conversion factors: independent laboratory access to the IS 
Despite the above mentioned efforts to standardize local protocols for BCR-ABL mRNA 
quantitation, (Gabert, 2003) there is still substantial variation among the various laboratories 
worldwide in the way RQ-PCR is performed and results are reported. (Cross, 2009, Müller, 
2007). Such variability is evident even among laboratories that use the same commercially 
available kit. Reasons for this variability include the fact that there is no universally 
accepted control gene and the absence of independent reference materials. The use of CFs as 
a means of harmonization has undoubtedly allowed testing centers to continue use their 
internal protocols and express results according to local preferences in addition to the IS 
percentage values. Nevertheless, the establishment of CFs is a time-consuming, complex, 
and expensive procedure. Moreover, the timing with which a certain CF needs to be 
revalidated is not defined (Müller, 2009). For these reasons, a collaborative project has been 
undertaken among 11 reference laboratories worldwide with the aim of developing 
calibrated, accredited primary reference reagents for BCR-ABL RQ-PCR analysis. The 
experts chose freeze-dried K562 cells as a source of BCR-ABL and HL60 cells, known to be 
BCR-ABL-negative, as a source of control genes, including ABL, BCR and GUSB, as 
recommended by the Bethesda group. They then created a cell line mixture consisting of 
K562 cells and HL60 cells and corresponding to %BCR-ABL/ABL values of 10%, 1%, 0.1%, 
and 0.01%. Cell mixtures proved to be stable over time at temperatures below 37°C and 
homogeneous in terms of material distribution at each %BCR-ABL/control gene. This work 
has produced 3500 vials for each dilution level. Since this would be insufficient for the 
worldwide annual demand, a decision has been made to use these primary reagents as 
reference for calibration of secondary reagents that could be produced on a larger scale by 
laboratories, companies or other agencies and provided to single testing centers (White, 
2010). Although of no immediate use, the development of primary reference reagents will be 
of great importance in the future to facilitate the production of more readily available IS 
calibrated reagents worldwide. 
4. Prognostic role of molecular remission 
The attainment of a CCyR has uniformly been shown to improve event free survival (EFS) 
and OS in CML patients receiving imatinib regardless of the baseline Sokal risk score, and 
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thus has been established as a robust endpoint for CML patients treated with imatinib in CP. 
However, conflicting data exist regarding similar prognostic value of MMR in this patient 
population. There is some evidence that the achievement of an MMR at 12 or 18 months 
after imatinib initiation, or at any time after CCyR predicts superior long-term clinical 
outcomes, as well as a significantly decreased risk of disease progression to more advanced 
disease stages (AP/BP). (Baccarani, 2009b; Deininger, 2009, Hughes 2010) It is true that, 
although OS should be considered the final endpoint in such clinical trials, sustained 
survival of CML patients in CP on TKi therapy implies that very long term follow-up may 
be needed for statistically significant differences in outcome to become apparent. For this 
reason, EFS, progression free survival (PFS), and transformation-free survival (TFS) are 
often used as surrogate endpoints.   
4.1 The prognostic role of cytogenetic remission 
Data from studies on CML patients treated upfront with imatinib 400 mg daily indicate a 
CCyR rate of 45 to 59% at 6 months, 57 to 72% at 12 months and 76% at 18 months (O'Brien,2 
003; Druker, 2006; Kantarjian, 2003, 2010; Saglio, 2010; Cortes, 2010a). Patients attaining a 
CCyR were protected from disease transformation, compared with those who did not 
achieve such response degree (Deininger, 2009). Several subsequent landmark analyses 
confirmed a shorter survival free of progression to AP/BP for patients not achieving a CCyR 
both at 12 and 18 months of therapy (O'Brien, 2003). However an OS advantage was seen 
only in patients who achieved at least a partial response at 6 and 12 months versus patients 
who did not (Kantarjian, 2008b). Increasing upfront the dose of imatinib to 800 mg daily 
could not provide any survival advantage (Baccarani, 2009a). 
4.2 CCyR duration is improved in patients who achieve an MMR 
Information on the prognostic implications of molecular response in CML patients in CCyR 
on imatinib therapy was provided by the IRIS study. In that trial, 39% of patients in CCyR 
on the imatinib arm achieved a 3-log reduction in BCR-ABL values. Landmark analysis at 12 
months in patients on imatinib without disease progression revealed that PFS was 100%, 
95% and 85% for patients with CCyR and 3-log BCR-ABL reduction (proposed as the 
definition of MMR), CCyR but no such reduction, and no CCyR, respectively (Hughes, 2003, 
2006). A synopsis of relevant studies analyzing the relationship between CCyR duration and 
level of molecular response is shown in Table 1. 
Paschka et al. analyzed 323 samples from 48 Ph-positive IFNǂ-pretreated CML patients 
receiving imatinib. CCyR was obtained in 41 cases. At the time of best response, overall 
median BCR-ABL/ABL ratio in peripheral blood was 0.086%, but best responses of patients 
destined to relapsed were significantly higher than those of patients in continuous CCyR, 
either globally considered or in CP only (1.4% vs 0.071%, p .0017 and 2.1% vs 0.075%, p 
.0011, respectively). More importantly, whereas all 16 patients who achieved a BCR-
ABL/ABL ratio of <0.1%were still in continuous CCyR at the time of writing, 6 (46%) patients 
with ratios ≥0.1%did lose their cytogenetic response, and this was the only significantly 
different parameter between the two groups. One possible weakness of this study is the 
shortness of follow-up, of only 13 (0-35) months, especially in light of the extremely 
sustained response durations seen with TKi therapy (Paschka, 2003).  
In line with these results, Iacobucci et al. assessed 97 CML patients in late CP for the 
duration of cytogenetic response according to the level of molecular response. BCR-ABL 
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transcript levels were significantly lower in patients maintaining their cytogenetic response, 
compared with those who subsequently relapsed. Moreover, with a median follow up time 
of 36 (12-54) months, CCyR duration was significantly longer in patients with MMR 
(defined as either an absolute BCR-ABL/ǃ2 microglobulin % value ≤ 0.0005 or a 3-log 
reduction from pre-treatment median population or individual BCR-ABL value) both at the 
time of first CCyR and at 12 months from the start of imatinib treatment. Patients with loss 
of CCyR also showed a significantly reduced 4-year OS compared with stable CCyR patients 
(60% vs 95%, p .0004) (Iacobucci, 2006). 
 
Study No.
Length of follow-up 
in months 
(median) 
% losing CCyR 
 
 
 
Pts with MMR 
at 12 months (%) 
Pts without MMR 
at 12 months (%) 
Paschka 2003 29 13 0 46 
Cortes 2005 280 31 5 37 
Iacobucci 2006 97 36 8 30 
Marin 2008 224 46.1 2.6 23.9 
Marin 2008* 224 46.1 0 24.6 
Press 2007 90 49 16 57 
Table 1. Selected studies of the impact of molecular response on the duration of CCyR; 
*analysis at 18 months 
Prognostic relevance of MMR with imatinib as first line has also been investigated (Cortes, 
2005). Two hundred eighty previously untreated CML patients in CCyR on imatinib therapy 
with at least 1 PCR test done for follow-up were observed for a median of 31 (3-52) months 
at the M.D. Anderson Cancer Center (MDACC). MMR and complete molecular response 
(CMR) rates were 62% and 34%, respectively. CCyR was lost by 9 (5%) and 25 (37%) patients 
who did or did not achieve MMR defined as a 0.05% value, respectively (p .0001). The 
percentage of patients losing their CCyR was not significantly different between MMR and 
CMR patients (Cortes, 2005). Press et al. reached similar conclusions. They evaluated 90 CML 
patients, using a 3-log drop in BCR-ABL values from baseline as a definition of MMR. With 
a median follow-up of 49 months after the initiation of imatinib, 20 (22%) patients relapsed. 
Once again, the median BCR-ABL level as detected by RQ-PCR was significantly lower in 
patients with future stable cytogenetic response compared with those who subsequently 
relapsed at every time point from 12 to 36 months. Relapse rate was 16% in patients who 
attained MMR and 57% in patients who never did. Accordingly, relapse-free survival was 
significantly shorter in patients who did not achieve an MMR (median 46 months) versus 
patients that did (median not reached at the time of writing; p.0008), and the hazard ratio for 
relapse was 4.1 (95% confidence interval, 1.7-10; p.002) (Press, 2007). The Hammersmith 
group also has published their data from a series of 224 consecutive CML patients, with 
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particular attention to patients failing or sub optimally responding to first-line imatinib 
according to the 2006 version of the recommendations of the European LeukemiaNet (ELN). 
When analyzing the effect of molecular response on the probability of losing a CCyR, they 
found that patients in CCyR who had failed to achieve MMR at 12 or 18 months had a 
higher CCyR loss rate than patients who did achieve MMR, (23.6% versus 2.6%, p .04 and 
24.6% versus 0%, p<.006, respectively (Fig.5) (Marin, 2008). It is to be noted that these 
recommendations have been updated in 2009, but long-term considerations on these 
changes cannot be made as of yet. 
 
  
 
 
Fig. 5. Twelve- and 18-months landmark analyses for loss of CCyR according to the level of 
molecular response. Vertical lines represent censored patients. Reprinted with permission; 
Marin et al., Blood 2008;112(12):4437-44.  
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4.3 Impact of molecular remission on long-term patient outcome 
In CML patients treated upfront with standard 400 mg imatinib daily, cumulative rates of 
MMR ranged from 12 to 40% at 12 months, and from 50 to 52% at 18 months in published 
studies. As previously mentioned, initial report from the IRIS trial on 370 patients (337 
receiving imatinib as first-line) showed a 12-month MMR rate of 39% across all Sokal risk 
groups, with PFS 100% for patients achieving both CCyR and MMR at a median follow-up 
of 25 months (O'Brien,2003; Hughes, 2010). Seven-year follow-up analysis of the same trial 
highlighted some important points: first, rates of molecular responses tend to increase with 
continuous imatinib therapy over time. At 84 months, MMR rates were 87-92% and BCR-
ABL/ABL ratio was 0.003-0.004% according to the IS (Hughes, 2010). Second, the virtually all 
MMR patients were also in CCyR at several timepoints. Third, and most importantly, at 12 
and 18 months, but not at 6 months, there was a statistically significant advantage in EFS 
and TFS for MMR versus non-MMR patients (EFS rate: 91 vs 79.4% and 94.9 vs 75.3%, 
respectively, at 12 months; TFS: 99 vs 89.9% and 99.1 vs 90.1%, respectively, at 18 months). 
However, when comparing MMR patients to those with BCR-ABL ratios of >0.1 to ≤1%, an 
advantage of EFS for the former was evident only at the 18 month time point (Fig.6), and 
TFS was only marginally significant. Moreover, in each comparison, OS did not differ 
significantly at every time point. 
 
 
 
 
Fig. 6. EFS at the 18-month landmark by molecular response. EFS definition does not 
include loss of CCyR. Reprinted with permission; Hughes et al., Blood 2010, Nov 
11;116(19):3758-65. 
Similar conclusions were reached by several other single center analyses. For example, when 
looking at molecular responses in their published series, the Hammersmith group found 
that, either considering the whole patient population or only patients in CCyR after 12 
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months of imatinib therapy, the achievement of MMR at 12 or 18 months did not translate 
into a 5-year PFS or OS advantage (Marin, 2008). Similarly, in the MDACC series of 269 
patients treated with imatinib upfront with more than 1 molecular evaluation available, 
molecular response at various timepoints did predict from survival (mainly PFS), but this 
was not independent from the degree of cytogenetic response, PFS only somewhat differing 
in MMR-CCyR patients (Kantarjian, 2008b). Taken together, these data led the ELN to 
express specific recommendations: that failure to achieve an MMR after 12 months of 
imatinib therapy be considered a “warning sign” (patients may require more frequent 
monitoring); that failure to achieve an MMR after 18 months of imatinib therapy be a 
criterion for defining “suboptimal” response (consider possible change in therapy). 
However, failure to achieve a MMR at any timepoint is never considered a treatment failure 
in the last version of the ELN guidelines (Baccarani, 2009).  
It is important to consider that landmark analyses are used to study patients achieving a 
certain level of response by a specific time point, different from treatment start and, by 
definition, they consider only patients who are on treatment and evaluable at that time. By 
doing so, a “better performing” population is always selected for the analysis. On the other 
hand, the definitions of cumulative CCyR, MMR, and CMR also include patients that meet 
such milestones only once over a long course of therapy with multiple serial evaluations. 
This way of reporting data may also provide a better than real picture of treatment efficacy, 
a bias avoided by landmark analyses. 
4.4 The role of early MMR 
Early identification of cancer patients failing on a certain therapy has become increasingly 
important in order to make potentially beneficial therapeutic adjustments before the end of 
treatment, and improve prognosis of patients otherwise destined to fare poorly. One such 
brilliant example is Hodgkin disease, in which a positive post-II cycle positron emission 
tomography (PET) can identify patients with dismal outcome and allow PET-oriented 
differential therapeutic strategies. In CML, several studies suggested that the degree of 
molecular response at early time points may predict later achievement of an MMR and, 
possibly, improved rates of PFS and EFS. Overall survival advantage for these patients, 
however, is little, if any, within the available follow up. Merx et al. demonstrated that a 
reduction of the BCR-ABL/ABL ratio to at least 20% of baseline after 2 months of treatment 
confers a significantly higher probability of major cytogenetic response (MCyR) later at 6 
months (Merx, 2002). In a separate analysis, although on a smaller number of patients, a 
BCR-ABL/ABL ratio reduction of 50% at 4 weeks, or a reduction of 90% at 3 months 
significantly predicted for the attainment of a MCyR at the 6 month time point. Also, with a 
median follow up of 16.5 months, there was suggestion that these achievements could 
predict better PFS. Branford et al. performed early and serial molecular follow up studies on 
55 evaluable CML patients treated with imatinib either upfront or after failure of 
IFNǂ+ARA-C. The authors found a median 1.6-log reduction after 3 months of first-line TKi 
therapy, not significantly different from second-line imatinib. They used the 2-log reduction 
cutpoint (grossly equivalent to a CCyR in the study) at 3 months to distinguish rapid from 
slow responders and observed that the former had a higher likelihood of achieving an MMR 
by 24 months (100% vs 54.2% p .001) (Branford, 2003a). Further confirmation of these 
findings came from an analysis conducted at the MDACC, showing that at time points 
progressively farther (ie, 3, 6, 12 months) from imatinib start, the probability of attaining a 
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CCyR for patients not yet at that point decreases, while in parallel the event rate increases. 
The probability of achieving a CCyR and a MMR by the degree of BCR-ABL/ABL ratio 
reduction showed that a reduction to at least 10% conferred a significantly higher likelihood 
of achieving such goal either at 3, 6 or 12 months. Moreover, when considering the 3 month 
cut point, 3 prognostic categories were distinguishable, ie, patients with a ratio of 1% or less, 
over 1% to 10%, and greater than 10%, with distinct probabilities of achieving CCyR and 
MMR (Quintás-Cardama, 2009) 
5. Early switch to second generation TKis 
As newer and more potent therapeutic options are being made available for CML 
patients, the need for early prediction of treatment failure is becoming more and more 
urgent, and the issue of early therapeutic switch in view of a non-satisfactory response 
has recently emerged as a crucial one. In fact, the above mentioned data suggest that 
treatment should not be continued indefinitely in patients not adequately responding to 
first-line imatinib as their likelihood of later response becomes progressively narrower, 
and especially early failure should prompt a change in the strategy. This concept is 
further reinforced by an analysis of the significance of suboptimal response to imatinib at 
different time points after the start of therapy. Such analysis was conducted in 281 CML 
patients mostly in early CP. Outcome of suboptimal responders in term of EFS tended to 
be more similar to that of failing patients at 6 months, whereas it was closer to the 
optimally responders thereafter (12 and 18 months). Likewise, the likelihood of achieving 
a MMR varied over time and tended to behave similarly to that of cytogenetic response 
(Fig. 7) (Alvarado, 2009). 
Options for patients failing on imatinib include switch to a second generation TKi, namely 
nilotinib or dasatinib, and, for those who are candidates, allogeneic bone marrow 
transplantation. There is data to suggest that waiting until clinical or hematological CML 
relapse may be too late for a switch. Patients who failed INFǂ therapy could obtain high 
response rates and survival times if they were treated with imatinib at the time of 
cytogenetic, rather than hematologic relapse (Kantarjian, 2002, 2004). In a subsequent 
analysis from MDACC, the 3-year survival rates were 72%, 30%, and 7% for patients who 
remained in CP, progressed to AP, or to BP after imatinib failure, respectively. Moreover, 
3-year survival rates were 92% and 57% for patients treated with second generation TKis 
at cytogenetic and hematologic relapse, respectively, with hematologic relapse, but not 
(yet?) therapy, being an independent poor prognostic factor (Kantarjian, 2007). A 
subsequent cumulative analysis of three, relatively homogeneous, dasatinib trials showed 
that patients treated with this second generation TKi at the time of loss of MCyR fared 
significantly better than those who received the drug when they had lost both MCyR and 
complete hematologic remission (CHR), or lost CHR having never attained an MCyR. For 
the three groups, CCyR rates were 72%, 42%, and 26% and MMR rates were 60%, 29%, 
and 26%, respectively. Twenty four month EFS, TFS, and OS were 89%, 98%, and 98%; 
29%, 93%, and 93%; 64%, 79%, and 86% for the same three patient groups, respectively 
(Quintás-Cardama & Cortes, 2009). Whether adjusting treatment strategy in patients 
categorized as suboptimal responders at various time points could be beneficial in terms 
of survival has not been established as yet and very long-term follow-up studies may be 
needed to demonstrate a statistically significant survival advantage applying this 
strategy.  
www.intechopen.com
 
The Value of Molecular Response in Chronic Myeloid Leukemia: The Present and the Future 
 
39 
 
 
Fig. 7. Event-free survival according to response at 6 (A), 12 (B), and 18 (C) months in 
patients treated with imatinib in early CP. Reprinted with permission; Alvarado et al., 
Cancer 2009, Aug 15;115(16):3709-18. 
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6. Role of molecular remission with second generation TKis 
As previously discussed, early molecular response on imatinib therapy predicts the 
probability of later achievement of an MMR, improved rates of PFS and EFS and lower the 
risk of disease transformation. Likewise, attainment of a precocious MMR may be a positive 
prognostic indicator for patients treated with the second-generation TKIs. Indeed, these 
agents have proven to work quicker than imatinib and to induce higher cytogenetic and 
molecular remission rates. This has provided the clinical rationale for successfully testing 
these agents as frontline treatment options for CML patients in chronic phase. Dasatinib 
(formerly BMS-354825) is 325-fold more potent than imatinib at inhibiting the unmutated 
form of BCR-ABL in vitro (O'Hare, 2005). This drug is chemically unrelated to imatinib and 
binds to BCR-ABL protein at a different but overlapping site (Tokarski, 2006). Nilotinib 
(formerly AMN-107) is 20-fold more potent than imatinib in vitro. It was developed through 
a modification of the chemical structure of imatinib and therefore binds to a very similar 
binding site on the BCR-ABL. However, it fits much better into the tertiary structure of the 
oncoprotein, and this enhances its biological activity (O'Hare, 2005; Weisberg, 2005). These 
two drugs were evaluated in single-arm phase I and II studies, first in patients with 
resistance or intolerance to imatinib (Quintás-Cardama, 2009a), and subsequently in the 
frontline setting. The trials showed that first-line treatment with dasatinib or nilotinib 
resulted in higher rates of CCyR and MMR earlier compared to what historically observed 
with imatinib (Cortes, 2010, 2010c). Results from two important phase III trials have been 
recently published comparing either dasatinib or nilotinib with standard dose imatinib as 
first-line treatment for patients with newly diagnosed CML in chronic phase. 
In the ENESTnd trial (Evaluating Nilotinib Efficacy and Safety in clinical Trials of Newly 
Diagnosed Ph CML patients), nilotinib was employed at two different dosages, ie 300 mg or 
400 mg twice daily. The primary endpoint of the study, MMR rate at 12 months, was largely 
met for both nilotinib dosages with MMR rates of 44%, 43% and 22% for nilotinib 300 mg 
twice daily, nilotinib 400 mg twice daily and imatinib, respectively (p<.001). CCyR rates by 
the same time point also significantly favored both nilotinib arms (80% for nilotinib 300 mg 
twice daily, 78% for nilotinib 400 mg twice daily, 65% for imatinib; both p<.001), and a 
similar trend for CCyR was evident at 6 months. Median time to MMR was 8.6 months with 
nilotinib 300 mg, 11.0 months with nilotinib 400 mg, and not reached with imatinib. Rates of 
BCR-ABL transcript reduction to or below the sensitivity limit of the PCR assay (set at ratio 
0.0032%, CMR) were 13%, 12%, and 4%, respectively (Saglio, 2010). A 24 month follow up of 
the study showed MMR and CMR rates of 71% and 26% vs 67% and 21%, vs 44% and 10%, 
respectively, for nilotinib 400 mg BID vs nilotinib 300mg BID vs imatinib. Estimated 
freedom from progression to AP/BC and PFS at 24 months were also significantly superior 
for both nilotinib arms (99.3 (p .0059) and 98.1(p .0196)) versus imatinib (95.2), although 
estimated OS rate advantage at 24 month did not reach statistical significance (Larson, 2011 ). 
In the DASISION trial (Dasatinib vs Imatinib Study in Treatment-Naive CML Patients), 
dasatinib 100 mg once daily was tested against imatinib 400 mg daily. Both CCyR and MMR 
rates at 12 months were significantly higher with dasatinib (CCyR: 83% vs 72%, p. 0011; 
MMR: 46% vs 28%, p. 0001). Rate of confirmed (c) CCyR by 12 months (the primary 
endpoint of the study) was also significantly increased (77% vs 66%, respectively; p. 0067). 
Importantly, CCyR rates at 3 and 6 months for dasatinib and imatinib were 54% vs 31% and 
73% vs 59%, respectively. Median time to MMR for patients who achieved this goal was 6.3 
months for dasatinib and 9.2 months for imatinib(Kantarjian, 2010). Recent update of this 
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study showed that 18-mo response rates for dasatinib versus imatinib were: cCCyR 78% vs 
70%, p .0366; CCyR 84% vs 78%, p.0932; and MMR 56% vs 37%, p<.0001. CMR rates for 
dasatinib and imatinib were 13% and 7%, respectively. Six (2.3%) vs 9 (3.5%) patients, 
respectively, transformed to AP or BP on study (Kantarjian, 2011a). 
The results of the trials described above clearly indicate that second generation TKis are able 
to achieve higher cytogenetic response rates and a substantially deeper leukemia clearance 
as demonstrated by the higher MMR rates and roughly doubled CMR rates in comparison 
with imatinib. Moreover, patients treated with nilotinib or dasatinib can achieve these 
important therapeutic milestones relatively early in the course of treatment, and, if the 
prognostic relevance of molecular remission will be confirmed, be possibly protected 
against the risk of loss of response and/or disease transformation later on. 
7. Treatment failure prediction 
Loss of molecular response at any time during therapy, as measured by confirmed rising 
BCR-ABL RNA levels, is considered a reliable criterion for prognosticating early treatment 
failure, and might influence an early treatment strategy change (Press, 2010). However, at 
this time, there is no uniform definition of what should be considered a “significant” rise in 
BCR-ABL transcript level (Kantarjian, 2009; Press, 2007). In their study, Press et al. found half-
log BCR-ABL increase (after adjusting for a 0.5-log interassay variability) as a threshold to 
predict for subsequent relapse as well as for shortened relapse-free survival. This retained 
its prognostic value even with imatinib dose escalation as a therapeutic response. Moreover, 
such an increase remained predictive of shortened relapse-free survival when considering 
only MMR patients (Press, 2007). 
A major cause of TKi treatment failure is the appearance of CML clones bearing BCR-ABL 
mutations that confer variable degree of insensitivity to the drug. For this reason, once rising 
BCR-ABL transcript levels are documented, screening for ABL kinase domain mutations is 
reasonable and recommended. A large number of different point mutations have been 
described over the last few years, affecting different spots in various domains of the BCR-
ABL oncoprotein. Mutations can be categorized into four groups, based upon the 
crystallographic structure of ABL: a) those which directly impair imatinib binding to the 
catalytic domain of oncogenic protein; b) those within the ATP binding site; c) those within 
the activation loop, which prevent the kinase from inactivating, required for imatinib 
binding; d) those within the catalytic domain (Baccarani, 2008). Mutations in the P-loop 
(G250E; Q252H, Y253F; E255K) may impart a particularly poor prognosis (Soverini, 2005, 
2011, Quintás-Cardama, 2006). Several technologies are available for the identification of 
BCR-ABL mutations. These include direct sequencing, subcloning and sequencing, 
denaturing high-performance liquid chromatography (D-HPLC), pyrosequencing, double-
gradient denaturing electrophoresis, allele-specific oligonucleotide PCR. Direct sequencing 
is the most widely applied. Briefly, the total RNA from whole blood leukocytes is reverse 
transcribed with random primers and the cDNA product is amplified with BCR/ABL –
specific primer set. The PCR product is then sequenced with ABL-specific primers. Standard 
dideoxy chain-termination DNA sequencing is performed and then analyzed using a 
specific software (Jones, 2008). The assay detects mutations in the ABL kinase domain 
between amino-acids 50 and 510. Direct sequencing has a detection limit of a mutation 
frequency of 20% (Branford, 2002; Hochhaus, 2002; Roche-Lestienne, 2002). Newly identified 
mutations should be confirmed by amplifying the normal ABL alleles to exclude 
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polymorphisms (Hughes, 2006). Various groups use higher sensitivity D-HPLC to routinely 
screen for kinase domain mutations, and then characterize them by sequence analysis 
(Soverini, 2004; Deininger, 2004). Strategies to circumvent mutation-induced imatinib 
resistance include imatinib dose escalation (Branford, 2003b) and switch to a second 
generation TKi. These drugs have proven particularly effective in this regard, since most 
BCR-ABL-mutated patient can still achieve a quick and high-quality cytogenetic and 
molecular response when crossed over nilotinib (Kantarjian, 2011b) or dasatinib (Quintás-
Cardama, 2009) after imatinib failure. The T315I mutation confers resistance to most TKis 
including nilotinib, dasatinib, and bosutinib (Shah, 2004).  
8. Complete Molecular Remission 
A proportion of patients in MMR on imatinib therapy, eventually achieve CMR, defined as 
undetectable BCR-ABL mRNA transcripts by real-time QPCR and/or NESTED/RT-PCR in 2 
consecutive high-quality samples (with sensitivity >104) (Baccarani, 2009b). CMR rates 
ranged from 4 to 41% in published studies. Such wide variability may be due to 
heterogeneity in treatment duration and dose, as well as in detection techniques employed. 
In the study by Press et al. 28 MMR patients on imatinib therapy eventually achieved CMR 
(3% and 18% of the entire cohort of patients at 12 and 24 months, respectively). Relapses 
occurred in 4% of CMR patients compared with 23% in MMR patients who failed to achieve 
CMR, with a median relapse-free survival of 44 versus not reached at the time of writing (p 
.0052). The achievement of a CMR, thus appears to define an excellent long-term prognosis 
and may be regarded as an optimal therapeutic goal (Press, 2007 ). Furthermore, with the 
use of second-generation TKIs (nilotinib and dasatinib) as frontline therapy for CML CP 
patients, even increased numbers of patients will ultimately achieve this level of response 
(Saglio, 2010 ; Cortes, 2009 Shah, 2004; Quintás-Cardama & Cortes 2008). 
There is ongoing effort to better define CMR from a quantitative standpoint in order to use 
and validate it as a surrogate survival endpoint. Indeed, the definition of PCR negativity is 
poorly standardized among laboratories and certainly the phrase “below the sensitivity of 
the assay” cannot be used as a reference standard because such sensitivity is laboratory-
specific by nature. Moreover, evidence that achievement of a CMR has an impact on long-
term EFS, PFS, or OS is limited, and more follow up is needed to draw any conclusion in this 
regard. In conclusion, the concept of CMR is still an evolving one, and the consistency of its 
prognostic value remains to be proved. 
9. Cure for CML? 
The absence of detectable BCR-ABL transcripts in a CML patient does not appear to indicate 
disease eradication. Ross et al. analyzed by DNA PCR 18 CML patients in sustained CMR 
after imatinib, who stopped therapy as part of a clinical trial (Ross, 2010). DNA PCR has the 
advantage of being a genomic test (RQ-PCR detects BCR-ABL mRNA in up to 30% of normal 
individuals), of being patient-specific, and of eliminating the risk of cross-contamination 
between samples. It has a sensitivity of around 1/106 (Biernaux, 1995). Seventeen of 18 
studied patients in CMR had a positive DNA PCR result at least once. Ten patients did 
relapse and these had an exponential increase in the levels of BCR-ABL DNA. However, the 
test had positive and negative predictive values of 62 and 75%, respectively, and thus 
limited value as a predictor of relapse (Ross, 2010). 
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Several studies have explored the possibility of discontinuing imatinib therapy in patients 
with long lasting CMR, but high relapse rates have been observed in these study 
populations. In the Australian CML8 study, of 18 early or late CP-CML patients, 5 did 
relapse after stopping imatinib, all within 5 months. CMR was regained in every instance 
upon resuming treatment (Ross, 2008). Recently, a prospective multicenter Stop Imatinib 
(STIM) study has been published by Mahon et al (Mahon, 2010), in which 100 CP or AP CML 
patients treated with imatinib for at least 3 years, in sustained CMR for at least 2 years, were 
asked to stop therapy and were molecularly monitored monthly for the first year and 
bimonthly for the second. Combination of imatinib with other agents such as IFNǂ or ARA-
C was permitted. Sixty nine of them had at least 12 months of follow-up. At a median follow 
up of 14 months, 42 of these patients relapsed molecularly after treatment discontinuation, 
mostly within 6 months, for a molecular relapse-free survival of 41% at 1 year, and 38% at 2 
years (Fig. 8). Only two patients had a fluctuation of their BCR-ABL levels and remained in 
CMR. Sex, Sokal score and imatinib treatment duration, but not previous IFNǂ therapy, 
were independent prognostic factors for the risk of molecular relapse. Taken together, these 
data indicate that relapse after imatinib cessation occurs relatively early in a substantial 
proportion of CML patients in sustained CMR, and argue against the discontinuation of 
imatinib therapy in responding CML patients outside the context of a clinical trial. Better 
characterization of patients with sustained molecular responses after stopping imatinib is 
needed, especially in comparison with those who subsequently relapse having the same 
baseline level of BCR-ABL transcript. The issue has not yet been addressed with the upfront 
use of second generation TKis and no comment can be made in this regard. 
 
 
Fig. 8. Kaplan-Meier estimates of complete molecular remission after discontinuation of 
imatinib in patients with chronic myeloid leukemia for the 69 patients at least 12 months of 
follow-up after discontinuation of imatinib. The estimated molecular relapse-free survival 
was 41% (29-52) at 12 months and 38% (27-50) at 24 months. Reprinted with permission. 
Mahon et al. Lancet Oncol, 2010. Nov;11(11):1029-35. 
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10. Conclusions 
Molecular monitoring of CML patients in CP receiving TKis as first-line treatment or after 
IFNǂ failure has emerged in recent years as a reliable, non-invasive diagnostic tool for 
assessing disease burden and treatment efficacy, and has replaced serial cytogenetic studies 
for these purposes. TKi therapy has dramatically increased the rates of high-quality 
response (ie, CCyR, MMR or CMR) compared to historical treatment options. Molecular 
studies, ie, RT- or RQ-PCR, allow appreciating this potency well under the threshold of 
classical cytogenetics. PCR protocols vary among different testing laboratories worldwide 
and may not provide fully comparable results and, ultimately, homogeneous measurement 
of treatment outcomes. The International Scale has represented a milestone in the 
achievement of harmonization of molecular monitoring and comparability of the test 
results. The first World Health Organization International Genetic Reference Panel for 
quantitation of BCR-ABL mRNA has been a major step forward in the standardization 
program allowing laboratory independent access to the IS. 
The achievement of a MMR has consistently been shown to predict for sustained CCyR in 
TKi treated CML patients, and is a marker of long-term EFS and PFS versus CCyR patients 
that do not reach this milestone. Whether this will translate into benefit remains to be seen 
and longer patient follow-up will be needed. In addition, early attainment of a significant 
BCR-ABL transcript level drop or a formal MMR may signify long-term protection from 
disease transformation into the AP/BP, and, possibly, survival benefit. Second generation 
TKis, namely dasatinib and nilotinib have recently been approved for first-line use in CML 
patients in chronic phase. These agents allow an even higher fraction of patients to enter 
MMR within 6 months of therapy, providing an additional strong rationale for their upfront 
employment. 
Confirmed rising BCR-ABL RNA levels, usually precedes cytogenetic and, eventually, 
clinical CML relapse, thus early predicting treatment failure, and prompting precocious 
strategy change. However, there is no consensus on when rise in BCR-ABL transcript level 
should be considered “significant”. BCR-ABL point mutation screening is recommended 
whenever a consistent transcript rise is documented and appropriate therapeutic action 
should be taken accordingly. 
Complete molecular remission may indicate the achievement of an even greater leukemic 
burden breakdown, but probably not yet disease eradication. Moreover, the definition of 
CMR has not been standardized yet, and its value as a positive prognosticator in CML 
patients treated with TKis in CP remains to be demonstrated. Finally, discontinuation of 
imatinib in patients with sustained CMR has been followed by disease relapse in more than 
50% of patients, and cannot be recommended at this time. 
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